Skip to content
Retatrutide360
JPFMD
Verified Physician ReviewerEndocrinology, Diabetes & Metabolism

Dr. Juan Pablo Frías, MD, FACE

Physician-Scientist & Clinical Trialist • Lead Medical Reviewer & Author at Retatrutide360

M.D. Vanderbilt UniversityUCSD Endocrinology FellowshipFellow of the AACE (FACE)150+ Peer-Reviewed PapersInvestigator: TRIUMPH, SURPASS, SURMOUNT
PubMed BibliographyGoogle ScholariDORCID ProfileLinkedIn

About Dr. Juan Pablo Frías

Juan Pablo Frías is a physician-scientist specializing in endocrinology, diabetes, and metabolism. He is widely recognized for leading and contributing to major clinical trials evaluating new treatments for type 2 diabetes, obesity, and related metabolic diseases, and has held leadership roles in both clinical research organizations and the biopharmaceutical industry.

Career and Training

Dr. Frías earned his M.D. from Vanderbilt University School of Medicine and completed a fellowship in Endocrinology, Diabetes, and Metabolism at the University of California, San Diego. He has served on the clinical faculty at UC San Diego and previously held academic appointments at the Barbara Davis Center for Diabetes at the University of Colorado. He has also directed large clinical research programs and has served as Chief Medical Officer, Head of Diabetes at Biomea Fusion.

Clinical Trial Leadership & Incretin Research

Dr. Frías has served as principal investigator for over 150 clinical trials evaluating novel metabolic therapeutics. His primary clinical investigations include:

  • Retatrutide Clinical Studies (TRIUMPH Trials): Investigating the novel GIP, GLP-1, and glucagon triple receptor agonist for chronic weight management and metabolic health, presenting clinical findings at international meetings including the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA).
  • Tirzepatide Clinical Programs (SURPASS & SURMOUNT): Leading pivotal phase 3 clinical investigations evaluating dual GIP and GLP-1 receptor agonism in patients with type 2 diabetes and obesity.
  • Semaglutide Investigations (STEP Trials): Evaluating once-weekly GLP-1 receptor agonism in metabolic and weight-reduction indications.
  • Metabolic Liver Disease (MASH/NASH): Investigating incretin and glucagon receptor agonists for hepatic steatosis and liver fibrosis reduction.

Role as Lead Author & Medical Reviewer

On Retatrutide360, Dr. Frías oversees clinical accuracy across all guides, calculators, and comparisons:

  • Primary Source Verification: Every percentage, milligram dosage, and clinical trial timeline is checked against primary peer-reviewed papers (NEJM, The Lancet) and regulatory documentation.
  • Dosing & Titration Protocols: Reviewing reconstitution guidelines, escalation schedules, and microgram-to-unit calculations to ensure patient safety and accuracy.
  • Adverse Effect Context: Contextualizing nausea, gastrointestinal events, and transient heart rate changes using actual clinical incidence rates from trials.
  • Trial Readout Updates: Ensuring guides are updated promptly when new Phase 3 data (such as TRIUMPH-1 and TRIUMPH-2) land.
Learn more about our review criteria on our Medical Review Process page.

Juan Pablo Frías is a physician-scientist specializing in endocrinology, diabetes, and metabolism. He is widely recognized for leading and contributing to major clinical trials evaluating new treatments for type 2 diabetes, obesity, and related metabolic diseases, and has held leadership roles in both clinical research organizations and the biopharmaceutical industry.

Career and training

Dr. Frías earned his M.D. from Vanderbilt University School of Medicine and completed a fellowship in Endocrinology, Diabetes, and Metabolism at the University of California, San Diego. He has served on the clinical faculty at UC San Diego and previously held academic appointments at the Barbara Davis Center for Diabetes at the University of Colorado. He has also directed large clinical research programs and has served as Chief Medical Officer, Head of Diabetes at Biomea Fusion.

Clinical trial leadership

As Medical Director and Principal Investigator at the Los Angeles Institute for Metabolic Research (LA-IMR) and Adjunct Clinical Professor of Medicine at Charles R. Drew University of Medicine and Science, Dr. Frías has led numerous Phase 1 through Phase 4 clinical trials. His investigations have contributed directly to the clinical understanding of multi-receptor incretin therapies:

  • Retatrutide investigations: Leading and presenting data from Phase 2 and Phase 3 TRIUMPH clinical trials evaluating GIP, GLP-1, and glucagon receptor agonism at major international meetings, including the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA).
  • Tirzepatide programs (SURPASS and SURMOUNT): Principal investigator on pivotal trials assessing dual GIP/GLP-1 receptor agonism in type 2 diabetes and chronic weight management.
  • Semaglutide programs (STEP): Clinical investigation of once-weekly GLP-1 receptor agonism for weight reduction and glycemic control.
  • Metabolic liver disease (MASH and MASLD): Clinical assessment of novel therapies targeting hepatic fat fraction reduction and metabolic stabilization.

Selected publications

Dr. Frías has authored or co-authored more than 150 peer-reviewed papers in high-impact medical journals:

  • Efficacy and Safety of Tirzepatide in Type 2 Diabetes (SURPASS-2). The New England Journal of Medicine, 2021.
  • Triple Hormone Receptor Agonist Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet, 2023.
  • Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England Journal of Medicine, 2021.
  • Incretin-based therapies in the management of obesity and metabolic syndrome. Diabetes Care, 2023.

Full publication histories are available on his PubMed Author Profile, Google Scholar, and ORCID record.

Medical review on Retatrutide360

Dr. Frías serves as lead author and medical reviewer for Retatrutide360. In this capacity, he reviews educational guides to ensure clinical precision:

  1. Trial data fidelity: Every percentage weight loss, glycemic reduction figure, and safety number is verified against published study tables.
  2. Titration and dosing protocols: Escalation schedules and reconstitution steps are checked against clinical study designs to avoid unsafe or unverified dosing recommendations.
  3. Symptom context: Adverse event reporting (including gastrointestinal symptoms, transient pulse increases, and cutaneous sensations) is grounded in clinical observation rather than forum conjecture.

For more details on our fact-checking standards, read our medical review process and our editorial policy.

Page last updated on September 27, 2026.